Jul. 30 at 9:08 PM
$TNXP Heading toward August 15 approval, I’m seeing a
$100 target price! momentum and catalysts make this a solid play.
$SLNX: A high-risk, high-reward gem with a
$6.5M market cap and
$11 share price. SIL-204, their lead RNAi therapy for KRAS-mutated cancers, showed 70–80% tumor reduction in preclinical studies. H2 2025 pancreatic cancer data could push SLNX into Phase 2/3 trials by 2026